CSIMarket
 
Ventyx Biosciences Inc   (VTYX)
Other Ticker:  
 
 
Price: $9.0000 $0.50 5.882%
Day's High: $9.3966 Week Perf: 48.76 %
Day's Low: $ 8.06 30 Day Perf: 301.79 %
Volume (M): 3,494 52 Wk High: $ 46.71
Volume (M$): $ 31,450 52 Wk Avg: $23.17
Open: $8.57 52 Wk Low: $1.87



 Market Capitalization (Millions $) 530
 Shares Outstanding (Millions) 59
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -181
 Cash Flow (TTM) (Millions $) -206
 Capital Exp. (TTM) (Millions $) 0

Ventyx Biosciences Inc
Ventyx Biosciences Inc. is a pharmaceutical company focused on the development of new treatments for a range of diseases including cancer, infectious diseases, and autoimmune disorders. The company was founded in 2013 and is headquartered in San Diego, California.

Ventyx Biosciences specializes in the development of innovative drugs that target specific molecular pathways involved in disease progression. The company has a strong research and development pipeline that includes both small molecule drugs and biologics.

One of the key areas of focus for Ventyx Biosciences is the development of drugs that target the PI3K/AKT/mTOR pathway, which is involved in a variety of diseases including cancer, cardiovascular disease, and neurodegeneration. The company has several candidates in preclinical and clinical development targeting this pathway, including VTX-01, which is being developed for the treatment of solid tumors.

In addition to its work on the PI3K/AKT/mTOR pathway, Ventyx Biosciences is also developing drugs that target the NF-kB signaling pathway, which is involved in inflammation and immune responses. The company's lead candidate in this area is VTX-02, which is being developed for the treatment of autoimmune and inflammatory diseases such as rheumatoid arthritis and psoriasis.

Ventyx Biosciences has a strong team of experienced scientists and executives with a track record of success in drug development. The company has also established collaborations with leading academic institutions and pharmaceutical companies to accelerate its research and development efforts.

Overall, Ventyx Biosciences is a promising biotech company with a strong pipeline of innovative drugs targeting diverse disease areas. The company is well-positioned to make a significant impact on the pharmaceutical industry in the coming years.


   Company Address: 12790 El Camino Real San Diego 92130 CA
   Company Phone Number: 593-4832   Stock Exchange / Ticker: NASDAQ VTYX
   VTYX is expected to report next financial results on March 11, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Ventyx Biosciences Inc

Headline: Exponential Growth of Outlays Power Ventyx Biosciences Inc in Fiscal Year Ending September 30, 2023



The pharmaceutical industry has always been known for its volatility, with companies facing ups and downs as they strive to develop groundbreaking treatments. Ventyx Biosciences Inc, a clinical-stage biopharmaceutical company, recently reported a significant operating deficit for the third quarter of 2023. While this news may initially sound concerning, the market participants have reasons to remain optimistic regarding the future prospects of the company.
Operating Deficit and Emerging Opportunities:
Ventyx Biosciences Inc faced an operating deficit of $-57.951 million, which represents a deterioration from the previous year. However, it is vital to note that the firm has not yet disclosed its top-line figures for the same reporting period. The speculation among market participants is whether the company will start demonstrating positive results in terms of revenue generation.

Ventyx Biosciences Inc

Ventyx Biosciences Inc Faces Financial Strain as Expenses Pile Up in Q2 2023


Introduction
Ventyx Biosciences Inc, a leading player in the Major Pharmaceutical Preparations sector, recently released its second-quarter financial results for 2023. The company's stock experienced a decline of -4.48% over the last five trading days. However, despite this setback, its year-to-date performance stands at an impressive 20.54%. Moreover, Ventyx Biosciences Inc's stock is trading on the NASDAQ at an 8.1% premium compared to its 52-week average. These figures provide a snapshot of the company's recent financial performance, but to gain a comprehensive understanding, it is vital to analyze the underlying facts and their potential impact on the company's future.
Financial Results Analysis
Observers in the Major Pharmaceutical Preparations sector are meticulously examining Ventyx Biosciences Inc's financial results for the second quarter of 2023. The company reported an operating deficit of $-57.145 million for the period spanning April to June 30, 2023. While no top-line figures have been provided yet, comparing this to the same period in 2022 offers valuable insight.

Ventyx Biosciences Inc

Working Costs in First Quarter of 2023 Surge at Ventyx Biosciences Inc, Exacerbating Ongoing Operating Deficit Concerns

Ventyx Biosciences Inc is a company that specializes in the production of major pharmaceutical preparations. The company has been experiencing a consistent operating deficit that has been a source of concern for both stockholders and investors. During the period between January to March 31, 2023, the stockholders did not anticipate any changes in revenue, but investors were concerned about the operating deficit, which was at $-42.552 million.
To relate the fiscal first-quarter outcome of 2023, it is essential to measure the operating the deficit of the first quarter of 2022, which was at $-22.747 million. This deficit has continued to be a major challenge for the company, and as a result, the CFO has been seeking different corporate policies to secure a steady product line.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com